Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aprecia Names Owen Murray as Its CEO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Aprecia Names Owen Murray as Its CEO

Most recently served in VP role at Recordati Rare Diseases.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Aprecia Pharmaceuticals has named Owen Murray as its new CEO. Murray will lead the expansion of Aprecia’s offerings in proprietary 3D-printed (3DP) pharmaceutical technologies.

“Owen has a unique background in both healthcare innovation and pharmaceutical commercialization,” said E. Thomas Arington, chairman, Aprecia. “His expertise will position Aprecia to further capitalize on exciting growth opportunities, by bringing value to partners and solutions to the unmet needs of patients around the world.”

Murray most recently served as the vice president of North American technical operations and quality assurance at Recordati Rare Diseases in New Jersey. Prior to joining Recordati, he held varying positions of increasing responsibility at Cardinal Health, Lundbeck, and Ovation Pharmaceuticals in Europe and the U.S. Murray has more than 25 years of experience in pharmaceutical and healthcare businesses, ranging from early product development through commercialization. He has successfully developed and led R&D, operations, supply chain, and quality operations teams.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters